Adaptive Biotechnologies (ADPT) Scheduled to Post Earnings on Wednesday

Adaptive Biotechnologies (NASDAQ:ADPTGet Free Report) is scheduled to be releasing its earnings data after the market closes on Wednesday, February 14th. Analysts expect Adaptive Biotechnologies to post earnings of ($0.27) per share for the quarter. Persons that wish to listen to the company’s earnings conference call can do so using this link.

Adaptive Biotechnologies (NASDAQ:ADPTGet Free Report) last announced its quarterly earnings data on Thursday, November 9th. The company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.03). Adaptive Biotechnologies had a negative return on equity of 47.62% and a negative net margin of 109.04%. The firm had revenue of $37.92 million for the quarter, compared to analyst estimates of $43.26 million. On average, analysts expect Adaptive Biotechnologies to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Adaptive Biotechnologies Trading Up 9.0 %

Shares of NASDAQ:ADPT opened at $3.77 on Wednesday. The firm has a market capitalization of $545.78 million, a PE ratio of -2.77 and a beta of 1.25. Adaptive Biotechnologies has a 1-year low of $2.61 and a 1-year high of $10.38. The business’s 50 day moving average is $4.50 and its 200-day moving average is $5.18.

Analyst Ratings Changes

Several research firms recently commented on ADPT. Piper Sandler cut their target price on Adaptive Biotechnologies from $13.00 to $6.00 and set an “overweight” rating for the company in a research report on Monday, November 13th. William Blair restated an “outperform” rating on shares of Adaptive Biotechnologies in a research report on Friday, November 10th. Finally, Morgan Stanley dropped their target price on Adaptive Biotechnologies from $13.00 to $10.00 and set an “equal weight” rating for the company in a research report on Tuesday, October 24th.

Get Our Latest Report on Adaptive Biotechnologies

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ADPT. Point72 Middle East FZE acquired a new position in shares of Adaptive Biotechnologies during the fourth quarter worth about $26,000. PNC Financial Services Group Inc. grew its position in shares of Adaptive Biotechnologies by 176.7% in the first quarter. PNC Financial Services Group Inc. now owns 5,293 shares of the company’s stock valued at $73,000 after purchasing an additional 3,380 shares during the last quarter. Meeder Asset Management Inc. grew its position in shares of Adaptive Biotechnologies by 407.8% in the fourth quarter. Meeder Asset Management Inc. now owns 5,632 shares of the company’s stock valued at $43,000 after purchasing an additional 4,523 shares during the last quarter. MetLife Investment Management LLC acquired a new position in shares of Adaptive Biotechnologies in the first quarter valued at approximately $90,000. Finally, Healthcare of Ontario Pension Plan Trust Fund acquired a new stake in Adaptive Biotechnologies during the first quarter worth approximately $100,000. 94.31% of the stock is owned by institutional investors and hedge funds.

Adaptive Biotechnologies Company Profile

(Get Free Report)

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals.

Featured Stories

Earnings History for Adaptive Biotechnologies (NASDAQ:ADPT)

Receive News & Ratings for Adaptive Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptive Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.